Genetic Analysis AS (GA) is positioned to become a world leader within the field of molecular in-vitro diagnostics of diseases related to gut imbalances. Based on the patented DNA-based GA-map® platform technology, profiles of patient’s gut microbiota is quickly generated and can be related to various health conditions. Our first product, the GA-map® Dysbiosis Test helps Gastroenterologists to measure and monitor gut microbiota status in patients with Irritable Bowel Syndrome (IBS). This is the first dysbiosis test which is commercially available, standardised, CE-marked and clinically validated (50 clinical trials + 30 publications). Further clinical applications for the tests are in areas such as diagnosis, disease severity course, treatment prediction and monitoring within both IBS (irritable bowel syndrome) and IBD (inflammatory bowel disease) where the need of clinical data and validation is required. GA is thus very active in these fields. Other areas of interest are metabolic disease including diabetes type 2

Weifa is Norway's leading consumer health company. We supply real value through medicines, lifestyle products and solutions that address the essential needs of consumers, customers and professional partners. Weifa was founded in 1940 and now employs about 30 highly qualified people at our headquarters in Oslo. The company has a strong position in Norway and is the market leader in pain relief, with well-established brands such as Paracet and Ibux. We are also present in other key areas such as dietary supplements and treatment for colds and respiratory problems.

NeoRad is a Norwegian medical device company built to improve patient care by providing quality, innovative and high-value medical products to the field of radiology. Our lead product, SimpliCT, aids radiologists in treating patients more accurately, quicker and by using less harmful radiation. Increased focus on image guided procedures, especially oncologic procedures are market drivers. “ Laser guidance significantly reduces fluoroscopy time and effective patient dose without affecting procedure time.” Maarten Kroes, MSc, Radboud University Nijmegen Medical Center, Holland, 2011